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In Brief
Plasmodium vivax malaria has been
difficult to study in the absence of animal
models. Mikolajczak et al. show that the
human liver-chimeric FRG KO huHep
mouse supports complete development
of P. vivax liver stages, including
hypnozoite formation and persistence
in vivo.
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Plasmodium vivax malaria is characterized by peri-
odic relapses of symptomatic blood stage parasite
infections likely initiated by activation of dormant
liver stage parasites—hypnozoites. The lack of trac-
table P. vivax animal models constitutes an obstacle
in examining P. vivax liver stage infection and
drug efficacy. To overcome this obstacle, we have
used human liver-chimeric (huHep) FRG KO mice
as a model for P. vivax infection. FRG KO huHep
mice support P. vivax sporozoite infection, liver
stage development, and hypnozoite formation. We
show complete P. vivax liver stage development,
including maturation into infectious exo-erythrocytic
merozoites as well as the formation and persistence
of hypnozoites. Prophylaxis or treatment with the
antimalarial primaquine can prevent and eliminate
liver stage infection, respectively. Thus, P. vivax-
infected FRG KO huHep mice are a model to investi-
gate liver stage development and dormancy andmay
facilitate the discovery of drugs targeting relapsing
malaria.
INTRODUCTION
The majority of human malaria is caused by infections with two
Plasmodium parasite species: Plasmodium falciparum and
Plasmodium vivax. Research efforts are predominantly focused
on P. falciparum malaria because of the high mortality the dis-
ease causes in sub-Saharan Africa. However, P. vivax malaria
affects more people in a wider geographical range (95 countries)
and puts 2.85 billion people at risk of disease every year (Guerra526 Cell Host & Microbe 17, 526–535, April 8, 2015 ª2015 Elsevier Inet al., 2010). Furthermore, recent studies indicate that P. vivax in-
fections are more pathogenic than previously appreciated (Price
et al., 2009). Two major attributes contribute to P. vivax’s unique
epidemiology: first, its ability to develop in mosquitoes at lower
temperatures; and second, the existence of dormant liver stages
termed hypnozoites that can be activated weeks, months, or
even years after the primary mosquito-transmitted infection.
Activated hypnozoites are thought to complete liver stage devel-
opment, leading to a relapse of symptomatic blood stage infec-
tion (White, 2011). Thus, it is of great importance to develop
experimental animal models that allow for the study of the bio-
logical features associated with the unique epidemiology of
this parasite.
Unfortunately, studies of the complex P. vivax liver stage
biology are encumbered by the parasite’s strong preference
for human and nonhuman primate tissue. The initial studies
describing P. vivax liver stages were performed on either human
liver biopsies of a patient undergoing experimental malaria fever
therapy for neurosyphilis (Shortt et al., 1948), or the liver biopsies
of chimpanzees infected by intravenous inoculation of a large
numbers P. vivax sporozoites (Krotoski et al., 1982b; Rodhain,
1956). It was the latter study (Krotoski et al., 1982b) that demon-
strated the existence of small, nonreplicating forms—hypno-
zoites (Markus, 2011)—in the P. vivax-infected liver. Since these
studies were undertaken, P. vivax liver stage research has been
sparse and mostly limited to in vitro studies in primary hepato-
cytes (Mazier et al., 1984) or hepatoma cell lines (Hollingdale
et al., 1985; Sattabongkot et al., 2006). Overall, little additional
knowledge has been gained to date that has yielded a better un-
derstanding of the biology of P. vivax hypnozoites and their role
in malaria relapse. These shortcomings negatively impact the
development of new antimalarial drugs, and as a result prima-
quine, an 8-aminoquinoline, is still the only licensed drug that
eliminates hypnozoites and offers causal prophylaxis and radical
cure treatment for P. vivax infection (Fernando et al., 2011). Addi-
tionally, P. vivax blood stages only replicate in reticulocytes, andc.
Figure 1. Development of P. vivax Liver Stages in the FRG KO huHep
Mouse
(A) Liver stage parasites in infected liver sections 3, 5, and 7 days after
sporozoite infection were visualizedwith differential interference contrast (DIC)
imaging (left panel), with a mAb specific for P. vivax circumsporozoite protein
(CS; VK247) (central panel), and DAPI for DNA content (right panel). To visu-
alize the DNA content in the small 3-day-old parasite, the area inside the
dotted box is enhanced in the top right corner.
(B) Liver stages at 3, 5, and 7 days after sporozoite infection were analyzed
with monoclonal mouse antibodies to P. vivax Upregulated in Infectious
Sporozoites protein 4 (UIS4, localizes to the PVM), acyl carrier protein (ACP,
localizes the apicoplast), heat shock protein 60 (HSP60, localizes to the
mitochondria), and binding immunoglobulin protein (BiP, localizes to the ER).
Scale bar, 10 mm.continuous in vitro blood stage culture remains extremely chal-
lenging. This further impedes studies of the parasite life cycle
(Carlton et al., 2011). Consequently, researchers have in the
past turned to the relapsing, nonhuman primate malaria parasite
Plasmodium cynomolgi to model the biology of hypnozoites
(Galinski et al., 2013). P. cynomolgi is genetically closely related
to P. vivax, and research on its liver stages led to the identifica-
tion of hypnozoites (Krotoski et al., 1982c; Shortt and Garnham,
1948). Recently, an improved in vitro culture system for
P. cynomolgi liver stages and hypnozoites was described (Dem-
be´le´ et al., 2014). Further refinements of such systems will
certainly contribute to drive a better understanding of the biology
of hypnozoites.
In search of P. vivax in vivo liver stage models, we took advan-
tage of a mouse that supports engraftment and long-term
survival of human primary hepatocytes (Azuma et al., 2007).
The severely immunocompromised FRG KO mouse (with dele-
tions in fumarylacetoacetate hydrolase [FAH], recombination-
activating gene 2 [Rag2], and interleukin-2 receptor subunit
gamma [Il2rg] gene deletions) can be transplanted with human
hepatocytes (FRG KO huHep). We have recently shown that
this mouse model supports the complete development of
P. falciparum liver stages, culminating in transition to blood stage
infection (Vaughan et al., 2012). Here we use the FRG KO huHep
mouse to show complete P. vivax liver stage development as
well as the formation and persistence of hypnozoites in vivo.
RESULTS
Infection of FRG KO huHep Mice with Plasmodium vivax
Sporozoites
FRG KO huHep mice were injected intravenously with 3.5–5 3
105 P. vivax sporozoites derived from mosquitoes that had
been infected with parasite isolates from Thailand. Mice were
sacrificed 3, 5, and 7 days postinfection. Infected liver tissue
was collected for histological evaluation and immunofluores-
cence assays (IFAs). The liver stages were initially localized
with a mouse monoclonal antibody (mAb) to the P. vivax circum-
sporozoite protein (CS, genotype VK247) (Rongnoparut et al.,
1995). Infections appeared robust, as indicated by the presence
of numerous liver stage parasites in individual liver sections (see
Figure S1A available online). CSwas expressed on the liver stage
parasite plasma membrane (PPM) and strongly confined to
the parasite periphery in a circumferential pattern at day 3 post-
infection (Figure 1A). It showed a more complex distribution at
days 5 and 7 postinfection (Figures 1A and S1B), presumably
due to the invagination of the PPM (Uni et al., 1985), which
precedes the formation of exo-erythrocytic merozoites. In
contrast, CS expression was not reported at late time points of
P. falciparum liver stage development in FRG KO huHep mice
(Vaughan et al., 2012), but it has previously been observed for
P. vivax liver stage development in vitro (Hollingdale et al.,
1985). To establish that P. vivax sporozoites infected and devel-
oped only in human hepatocytes within the mouse liver, we cos-
tained the infected liver sections with a FAH-specific polyclonal
antibody, which only identifies human hepatocytes (FRG KO
mouse hepatocytes lack FAH). Indeed, liver stages were exclu-
sively detected in human hepatocytes at all time points of devel-
opment (Figure S1C).CellThe Complex Cellular Organelle and Membrane
Development in P. vivax Liver Stages Is Revealed
with Antibodies
To reveal the cellular features of P. vivax liver stages, we devel-
oped polyclonal rabbit and monoclonal mouse antibodies spe-
cific to P. vivax proteins or conserved Plasmodium proteins
that have a high amino acid sequence identity among orthologs
(Figures 1B and S2A). One prominent feature ofPlasmodium liver
stages is the establishment of the parasitophorous vacuole
membrane (PVM), which separates the parasite from the cyto-
plasm of the host hepatocyte. To visualize the P. vivax PVM,Host & Microbe 17, 526–535, April 8, 2015 ª2015 Elsevier Inc. 527
Figure 2. Complete Maturation of P. vivax Liver Stages and Blood
Stage Transition in the FRG KO huHep Mouse
(A) Indirect immunofluorescence assay (IFA) of P. vivax liver stages at 10 days
after sporozoite infection using Pv merozoite surface protein 1 (MSP1), poly-
clonal rabbit antibody (green), PvUIS4 mouse monoclonal antibody (red), and
DAPI (blue, DNA).MSP1 expression reveals the presence of differentiated exo-
erythrocytic merozoites within the liver stage schizont. The magnification of
the area in the yellow box shows a MSP1-positive exo-erythrocytic merozoite
(arrow) outside the confines of the mature liver schizont. Scale bar, 10 mm.
(B) IFA of a 9-day-old P. vivax liver stage stained with PvMSP1 polyclonal
rabbit antibody (green) to visualize the merozoite surface, ACP monoclonal
mouse antibody (red) to visualize the apicoplast, and DAPI (DNA stain, blue).
The mature liver stage is in the process of releasing exo-erythrocytic mero-
zoites into the surrounding liver tissue. Scale bar, 20 mm.
(C) Human red blood cells enriched for reticulocyteswere injected into FRGKO
huHep mice 9 and 10 days post-sporozoite infection. Four hours after the
second injection, the blood was removed and microscopically analyzed by
Giemsa-stained thin blood smear. Black arrows point to P. vivax ring stage
parasites within reticulocytes. Scale bar, 10 mm.we produced a mouse mAb against the P. vivax ortholog
(PvUIS4) of P. yoelii Upregulated in Infectious Sporozoite 4
(UIS4), which was previously shown to localize to the PVM of
rodent malaria parasite liver stages (Mueller et al., 2005). The
PvUIS4 mAb revealed a circumferential staining pattern that
ensconced the liver stages (Figure 1B) and was distinct from
CS (a PPMmarker) (Figure S2B), indicating that PvUIS4 localizes
to the PVM. Furthermore, previously unstudied organelles of
P. vivax liver stages were detected using mouse mAbs to (1)
the relict plastid (apicoplast)-targeted acyl carrier protein
(ACP); (2) the mitochondrial heat shock protein, HSP60; and (3)
the endoplasmic reticulum (ER)-targeted protein binding immu-
noglobulin protein (BiP) (Figure 1B). As liver stage schizogony
progressed, the organelle structures became highly complex,
consistent with their extensive replication. The PV lumen was
localized with a rabbit polyclonal antibody to falstatin (P. vivax
ortholog of P. yoelii falstatin; Pei et al., 2013), the parasite cyto-
plasm was visualized with rabbit polyclonal antibody to macro-
phage inhibitory factor (MIF) (P. vivax ortholog of P. yoelii MIF;
Miller et al., 2012), and the Golgi apparatus localized with anti-
body the ER lumen protein retaining receptor (ERD2) (Elmendorf
and Haldar, 1993) (Figure S2A).
Complete Maturation of P. vivax Liver Stages, Infectious
Exo-erythrocytic Merozoite Release, and Reticulocyte
Invasion
The duration of P. vivax liver stage development culminating in
the formation and release of infectious exo-erythrocytic merozo-
ites remains imprecisely defined. Analysis of P. vivax liver
stage schizogony in the FRG KO huHep mice at day 7 and day
8 post-sporozoite infection showed that liver stage maturation
was not yet complete. This contrasts with observations of
P. falciparum liver stage maturation in this mouse model where
release of exo-erythrocytic merozoites occurred between 6
and 7 days post-sporozoite infection (Vaughan et al., 2012). In
P. falciparum, the expression of MSP1 precedes exo-erythro-
cytic merozoite formation and clearly identifies the surface of in-
dividual exo-erythrocytic merozoites (Vaughan et al., 2012). We
thus analyzed P. vivaxMSP1 expression in liver stage schizonts
and observed expression as early as day 5 post-sporozoite
inoculation, with increased expression at day 8 (Figure S2C).
However, individual merozoites were not observed. Continued
analysis of liver stage schizogony showed numerousmature liver
stage schizonts at day 9 that contained individual exo-erythro-
cytic merozoites (Figure 2A). Some mature schizonts had
released merozoites in tightly packed masses that were
observed in the surrounding tissue, beyond the confines of
what appeared to be a ruptured PVM (Figure S3A). The majority
of mature liver stage schizonts lost their characteristic spherical
structure and released a substantial fraction of their exo-erythro-
cytic merozoites into the surrounding tissue, including the liver
sinusoids (Figure 2B). Mature liver stage schizonts were also de-
tected at day 10 post-sporozoite infection, but they were fewer
when compared to day 9 (data not shown). The remaining liver
stages had clearly differentiated apicoplasts, suggesting that
they were close to maturation (Figure S3B). The decline in liver
stage schizont numbers at day 10 compared to day 9 was likely
the result of mature parasite egress from hepatocytes, leaving
fewer schizonts in the tissue. Therefore, we conclude that the528 Cell Host & Microbe 17, 526–535, April 8, 2015 ª2015 Elsevier Incomplete maturation of P. vivax liver stages and exo-erythrocytic
merozoite release occurs between day 9 and day 10 post-sporo-
zoite infection in the FRG KO huHep mouse model. To test
whether exo-erythrocytic merozoites released from the liver
can invade red blood cells to continue the parasite life cycle,
mice were intravenously injected with reticulocytes at days 9
and 10 after sporozoite inoculation (this experiment was per-
formed twice with two mice per group). Four hours after the sec-
ond reticulocyte injection, blood was removed from each mouse
by cardiac puncture and analyzed for parasites by Giemsa-
stained thin blood smears. Ring stage parasite-infected reticulo-
cytes were readily observed for each mouse tested (at least 20
separate thin blood smears were made from each mouse and
parasite-infected reticulocytes were seen in all smears; Fig-
ure 2C). Thus, P. vivax liver stagematuration and release of retic-
ulocyte-infectious exo-erythrocytic merozoites can be modeled
using FRG KO huHep mice.
Formation of P. vivax Hypnozoites in the FRG KO huHep
Mouse Liver
During the analysis of liver stage schizont growth at days 5–8
post-sporozoite infection, we also detected a subset of liverc.
Figure 3. Characterization of P. vivax Hyp-
nozoites in the FRG KO huHep Mouse and
Comparison to Sporozoites
(A) IFA of P. vivax sporozoites stained with mouse
monoclonal antibody to PvCS (green) and rabbit
polyclonal antibodies to PvUIS4, BiP, PvHSP60,
ACP, and Pv MIF (red).
(B) Hypnozoites at day 7 post-sporozoite infection
were localized with antibodies to PvUIS4 (rabbit
polyclonal and mouse monoclonal) (green),
monoclonal mouse antibody to PvCS (red), and
rabbit polyclonal antibodies to BiP, PvHSP60,
ACP, and PvMIF (red). The yellow arrow points to a
PvUIS4-postive PVMprominence that is notable in
the PVM of all hypnozoites. Scale bar, 10 mm.stage parasites that were small at all time points and appeared
not to increase significantly in size (Figure 3). We concluded
that these were small, nonreplicating hypnozoite forms and for
the ease of terminology will refer to these small forms as hypno-
zoites. At the time of exo-erythrocytic merozoite release at
days 9 and 10 postinfection, hypnozoites continued to persist
(Figure S3A). To confirm that hypnozoites resided within human
hepatocytes and not to remaining mouse hepatocytes, which
could retard liver stage development, we used an antibody to
detect human FAH in the infected liver sections. Indeed, all
observed hypnozoites were located within human hepatocytes
(Figure S1C).
To determine if P. vivax hypnozoites display any unique organ-
ellar features that would differentiate them from sporozoites and
replicating liver stage schizonts, we performed IFAs on sporozo-
ites (Figure 3A) and hypnozoites at days 5, 7, and 8 post-sporo-
zoite infection (Figure 3B). Mouse mAbs and rabbit polyclonal
antibodies to PvUIS4, BiP, PvHSP60, ACP, and PvMIF were
used to characterize protein expression and localization. As ex-
pected, the ER marker BiP and the mitochondrial marker HSP60
were localized to the sporozoite interior (Figure 3A), as has been
described for sporozoites of other Plasmodium species. Inter-
estingly, PvUIS4 was not detected in P. vivax sporozoites, in
contrast to observations made for P. yoelii UIS4 (Kaiser et al.,
2004) and P. falciparum UIS4 (Mackellar et al., 2010) but in
agreement with P. berghei UIS4 (Silvie et al., 2014). Expression
of ACP and PvMIF was also not observed in P. vivax sporozoites
(Figure 3A). As opposed to sporozoites, UIS4 was readily de-
tected in hypnozoites in a circumferential pattern, indicative of
PVM localization (Figure 3B). Intriguingly, PvUIS4 staining always
revealed a polarized densely fluorescent prominence of the PVM
(Figure 3B, yellow arrows), which was never observed on the
PVM of liver stage schizonts at all time points examined (Figures
1B and S2A and data not shown). Moreover, the PVM promi-
nence was also not observed on liver stage trophozoites atCell Host & Microbe 17, 526–day 2 post-sporozoite infection (two
mice infected with two independent
P. vivax isolates) (Figure S3C). Thus, the
UIS4-positive PVM prominence might
be a unique feature of P. vivax hypno-
zoites. The localization patterns for BiP,
HSP60, and ACP suggested that biogen-esis of the ER and initial replication of mitochondria and apico-
plast had commenced in hypnozoites (Figure 3B). However,
the hypnozoite organelles were more limited in their replication
when compared to early liver stage schizonts at day 3 post-
sporozoite infection (Figure 1B). Interestingly, ACP and PvMIF
were expressed in hypnozoites, but not in sporozoites (Figure 3).
Furthermore, exported protein 1 (EXP-1), another PVM-resident
protein (Doolan et al., 1996; Vaughan et al., 2012), was not ex-
pressed in sporozoites, hypnozoites, or day 3 liver stage schiz-
onts but was clearly detected in liver stage schizonts starting
at day 5 post-sporozoite infection (Figure S4A). This expression
pattern contrasted with the PVM protein, PvUIS4, which was ex-
pressed by all P. vivax liver stages observed, including hypno-
zoites (Figure 3B).
Next, the extent of genome replication was analyzed in hypno-
zoites. We encountered difficulties in visualizing hypnozoite DNA
byDAPI due to the high fluorescent intensity of hepatocyte nuclei
in the infected liver sections and comparatively minute DNA con-
tent of hypnozoites. Therefore, to indirectly analyze the extent of
DNA replication in hypnozoites, a histone acetylation-specific
antibody (recognizing acetylated lysine 9 of histone H3,
H3K9Ac) was used for IFA (Figure 4). A single histone-positive
structure was observed in hypnozoites, suggesting that they
had not undergone significant DNA replication. This was in stark
contrast to replicating liver stage schizonts, which exhibited an
increasing number of histone-positive structures with progres-
sive growth over the course of infection, starting as early as
day 3 after sporozoite infection (Figure 4).
The Persistence of P. vivax Hypnozoites and Hypnozoite
Activation
To investigate if hypnozoites persisted in the mouse model, we
analyzed livers at days 14 and 21 post-sporozoite infection. At
day 14, persistent hypnozoites were present (Figures S4B and
5B), and importantly, no liver stage schizonts were observed at535, April 8, 2015 ª2015 Elsevier Inc. 529
Figure 4. P. vivax Liver Stage Genome Replication
Antibodies to acetylated lysine 9 of histone H3 (H3K9Ac) (green) were used to
analyze genome replication of liver stage parasites in infected FRG KO huHep
mice. Schizonts and hypnozoites were also stained with antibody to CS
(VK247) (red). DNA was visualized with DAPI (blue). A single H3K9Ac-positive
structure was detected within liver stage trophozoites 2 days after sporozoite
infection. Hypnozoites (shown here 5 days after sporozoite infection) also
contained a single H3K9Ac-positive structure. Multiple H3K9Ac-positive
structures were observed for replicating liver stage schizonts at days 3, 5, and
7 after sporozoite infection. Scale bar, 10 mm.
Figure 5. P. vivax Hypnozoite Persistence and Activation in FRG KO
huHep Mice
(A and B) Persistent hypnozoites at day 21 after sporozoite infection. Parasites
were visualized with antibodies to PvUIS4 (green) and antibodies to apico-
plast-localized ACP and acetylated lysine 9 of histone H3 (H3K9Ac) or ACP
(red). Host hepatocyte nuclei were visualized with DAPI. The UIS4-postive
PVM prominence is maintained and notable in the PVM of all persistent hyp-
nozoites. Hypnozoites contained a single H3K9Ac-positive structure.
(C) Size comparison of liver stage trophozoites, liver stage schizonts, and
hypnozoites at different time points of infection. The size (liver stage area at the
greatest circumference of the parasite) was calculated. Measurements were
taken for at least ten liver stages at each time point. The average size ± SEM
is shown on the dot plots. Note that hypnozoites show growth over time
but remain smaller than 3-day-old schizonts. No schizonts were detected
in infections at 14 days after sporozoite infection but were again detected at
day 21.
(D and E) Shown are examples of replicating liver stage schizonts at day 21
post-sporozoite infection, suggesting that they originated from hypnozoites
that activated and entered schizogony. Antibodies used for IFA were mouse
monoclonal antibody to PvUIS4 (green) rabbit polyclonal antibodies to ACP in
the left panel and H3K9Ac (red) in the right panel. DNA was stained with DAPI
(blue). Scale bar, 10 mm.this time point (Figure 5C). Furthermore, no parasite-infected
human reticulocytes were recovered when the day 14 sporo-
zoite-inoculated mice were transfused with human reticulo-
cyte-enriched blood and analyzed as described above (data
not shown). We also observed multiple hypnozoites at day 21
postinfection (five mice evaluated; >20 hypnozoites observed
in 30 sections from each liver) (Figures 5A–5C). Day 21 hypno-
zoites were somewhat larger when compared to hypnozoites
detected during the first 10 days of infection (Figure 5C) but still
showed no evidence of DNA replication based on detection of a
single H3K9Ac-positive structure in each hypnozoite (Figure 5B).
Interestingly, day 21 hypnozoites exhibited multiple, apparently
individualized apicoplasts (Figure 5A). All persistent hypnozoites
showed the unique UIS4-positive PVM prominence (Figures 5A,
5B, and S4B). Hypnozoites were not distinguishable at day 2
postinfection, when all parasites were at trophozoite stage
but could be clearly distinguished from replicating schizonts at
day 3 postinfection onward (Figure 5C). Hypnozoites from all
analyzed time points of infection remained smaller in size than
liver stage schizonts detected at day 3 postinfection (Figure 5C).
Strikingly, we observed a total of three liver stage schizonts
in multiple liver sections analyzed from day 21 infections530 Cell Host & Microbe 17, 526–535, April 8, 2015 ª2015 Elsevier In(>30 sections analyzed in five independently infected mice)
(examples are shown in Figures 5D and 5E). These schizonts
were not yet fully mature and were similar in size to schizonts
observed at days 5–7 post-sporozoite infection (Figures 1B
and 5C).c.
Figure 6. Thai P. vivax Hypnozoite Frequencies and Outcomes of
Experimental Drug Treatments in FRG KO huHep Mice
(A) A graphical representation of hypnozoite and liver stage schizont abun-
dance in infections. Liver stages are denoted as schizonts or hypnozoites. For
quantitative assessment, liver stages observed on ten nonserial liver sections
were totaled for each infected mouse. Results for two Thai P. vivax CS ge-
notypes are shown CS VK247 genotype (two independent experiments with
different patient isolates) and CS VK210 genotype (four independent experi-
ments with different patient isolates). PF NF54, P. falciparum NF54 liver stage
assessment at day 7 post-sporozoite infection. Error bars, standard deviation.
(B) Four mice were treated with primaquine (30 mg/kg) at days 1–3 post-
sporozoite infection (PQ prophylaxis, P) or days 3–7 post-sporozoite infection
(PQ treatment, T). Parasites of the CS VK210 genotype were used for the
experiments. Four untreatedmice served as controls (Control). Eight days after
sporozoite infection, all mice were sacrificed, and cDNA was produced from
three separate liver tissue samples for each mouse. Liver stage burden using
qRT-PCR andwas used to normalizeP. vivax 18S rRNA transcription to human
ApoAI transcription. The graph insert shows microscopic quantitation of liver
stage schizonts and hypnozoites observed by IFA. Area of tissue refers to
cumulative area of tissue analyzed for each treatment where similar number of
sections from each technical replicate was processed.The Frequency of Hypnozoite Formation
in Thai P. vivax Isolates
Hypnozoites remain nonreplicating and much smaller than repli-
cating liver stage schizonts, and persist after commencement of
the primary liver stage infection (Figure 5C). Hypnozoites also
possess unique cellular characteristics that can be readily visu-
alized by antibody staining (Figure 4). To determine hypnozoite
frequencies for the Thai P. vivax isolates used for infections,
we calculated their fraction in the total number of liver stage
parasites (schizonts + hypnozoites) at days 5–7 of infection.
We observed that infections performed with P. vivax isolates
of the CS VK247 genotype (experiment performed twice with
two mice per independent experiment and individual VK247 iso-
lates) yielded a hypnozoite frequency of approximately 40%
(Figure 6A), closely matching the hypnozoite frequency of 50%Cellpredicted (but never formally shown) for tropical strains of
P. vivax (White, 2011). This hypnozoite frequency did not
change significantly between 5 and 7 day infections or mice
that were repopulated using different hepatocyte donors, indi-
cating that hypnozoite frequencies are maintained with progres-
sion of infection in the FRG KO huHep model (Figure S5A).
Strikingly, however, in another set of infections with Thai
P. vivax isolates of the CS VK210 genotype, the hypnozoite fre-
quency was drastically different, averaging only 8% (four inde-
pendent infections with at least two mice per infection; Figures
6A and S5A).
Testing P. vivax Liver Stage Drugs in the FRG KO huHep
Model
We next explored the FRG KO huHep model as a platform for
testing drugs against P. vivax liver stages. In addition to evalu-
ating liver stage burden by histological examination, we also
developed a quantitative real-time PCR (qPCR) assay based
on the detection of P. vivax 18S ribosomal RNA (normalized
against human apolipoprotein AI to account for hepatocyte
humanization of the liver). Primaquine is currently the only
licensed drug that has demonstrated efficacy to prevent re-
lapses and affords causal prophylaxis as well as treatment for
P. vivax infections of the liver. We treated a group of four mice
with primaquine (30 mg/kg; intravenously) for 5 days, starting
1 day before P. vivax sporozoite infection (CS VK210 genotype)
as a prophylaxis regimen. A second group of mice was treated
with an equivalent primaquine regimen starting on day 3 post-
sporozoite infection, to assess elimination of established hypno-
zoites. The mice were sacrificed at day 8, and the efficacy of
the drug to eliminate P. vivax liver stage infection relative to
control, four untreated P. vivax-infected mice, was evaluated
by qPCR. In untreated control mice, P. vivax liver stage burden
was robustly detected by qPCR (Figure 6B). In seven out of
eight primaquine-treated, P. vivax-infected mice, liver stage
parasites were undetectable by qPCR (Figure 6B). One mouse
in the prophylaxis group showed a very low signal for parasite
18S rRNA. Histological analysis of multiple liver tissue sections
from all mice readily detected P. vivax liver stage schizonts and
hypnozoites in untreated control livers. No schizonts or hypno-
zoites were detected in the livers of primaquine treated mice,
including the liver that showed residual parasite 18S rRNA signal
by qPCR analysis (Figure 6B). We also investigated the effect of
atovaquone, a drug that eliminates replicating liver stages but
does not prevent relapses, on P. vivax liver stages in the FRG
KO huHep mouse model. We treated a group of three mice
with atovaquone (10 mg/kg; orally) for 3 days, starting 1 day
before P. vivax sporozoite infection (Figure S5B). The mice
were sacrificed at day 8, and the effect of the drug on P. vivax
liver stage infection relative to control—two untreated P. vivax-
infected mice—and the primaquine prophylaxis regimen (three
mice in a prophylaxis regimen described above) was analyzed.
Histological analysis of multiple liver tissue sections from mice
treated with atovaquone showed that P. vivax liver stage schiz-
onts were almost completely absent (one schizont detected) in
the mice. However, establishment of hypnozoites was not
affected by atovaquone (Figure S5B). In contrast, primaquine
prevented establishment of hypnozoites and replicating liver
stages (Figure S5B).Host & Microbe 17, 526–535, April 8, 2015 ª2015 Elsevier Inc. 531
DISCUSSION
Activation of dormant hypnozoites, subsequent liver stage schi-
zogony, exo-erythrocytic merozoite release, and concomitant
blood stage infection (relapse) constitutes a major determinant
of the unique P. vivax epidemiology (White and Imwong, 2012).
Yet, P. vivax hypnozoites and their occurrence, frequency,
dormancy, and activation remain mostly unexplored. Since pio-
neering studies described P. vivax liver stages in humans and
Aotusmonkeys (Collins et al., 1973; Shortt et al., 1948) and hyp-
nozoites in infected chimpanzees (Krotoski et al., 1982b), little
progress has been made in this area of research, despite the
global importance of vivax malaria.
Here, we have shown that the human liver-chimeric FRG KO
huHep mouse model provides a unique opportunity to advance
our understanding of P. vivax liver stage biology. This model sup-
ports robust infection with P. vivax sporozoites and the develop-
ment of liver stages, both nonreplicating hypnozoites that persist
and replicating schizonts that develop to completion and release
infectious exo-erythrocytic merozoites. One of the advantages
of the model is its small size. In consequence, with only a few
hundred thousand P. vivax sporozoites, a robust liver stage
infection can be achieved, and infection is amenable to quantita-
tive analysis by microscopy and PCR. Thus, the model also
enables testing of drugs that prevent the establishment of hyp-
nozoites or that eliminate established hypnozoites. Although
in vitro models for P. vivax liver stage research have improved
with the advent of microscale primary hepatocytes cultures
(March et al., 2013), the FRG KO huHep mouse model will be
extremely valuable to study P. vivax liver stage biology and test
drugs in vivo.
We have presented numerous lines of evidence that P. vivax
infections in the mouse model result in the formation and persis-
tence of hypnozoites. Intriguingly, our data indicate that inde-
pendent P. vivax isolates from the same geographical area in
Thailand differ in their hypnozoite frequencies, and this appears
to be associated with their genotype. It is known that P. vivax iso-
lates from temperate regions relapse with longer time intervals to
first event and also show longer periodicity when compared to
tropical strains, which show short relapse frequencies (reviewed
in White, 2011). It is possible that longer relapse periodicity is a
parasite adaptation to the seasonal availability of vectors for
transmission. The significance of the different hypnozoite fre-
quencies we have seen for Thai P. vivax isolates is currently
not understood, and it will be of interest to further explore the
question of why parasites in the same geographic area would
show heterogeneity in this important biological aspect of liver
infection. The robust P. vivax liver stage infections we have
observed will allow future quantitative investigation of hypno-
zoite frequencies from P. vivax strains of different geographical
origin. This analysis should contribute to unraveling the relation-
ship between clinically observed relapse patterns and hypno-
zoite frequencies in different parts of the world.
Antibodies to a diversity of parasite proteins allowed a detailed
cellular characterization of P. vivax liver stages. Previous studies
relied on immune sera from patients living in P. vivax-endemic
areas (Krotoski et al., 1982b) and more recently CS specific
antibodies (Rosenberg et al., 1989). The antibodies revealed
the PVM, apicoplast, mitochondria, ER, and Golgi throughout532 Cell Host & Microbe 17, 526–535, April 8, 2015 ª2015 Elsevier Inliver stage development and also allowed for an unprecedented
characterization of hypnozoites. Hypnozoites exhibited a PVM
with a unique UIS4-positive prominence, a feature not observed
in developing liver stage schizonts or early trophozoite stages. It
is tempting to speculate that this structure constitutes a unique
point of interaction between the hypnozoite and its host hepato-
cyte, but this remains to be investigated. Of equal interest,
hypnozoites showed evidence for active cellular processes,
including development of the ER and initial replication of mito-
chondria and the apicoplast. Hypnozoites also increased, albeit
modestly, in size during the time course of infection (3–21 days
after sporozoite infection). Together, these findings challenge
the prevailing notion that hypnozoites are truly dormant. Never-
theless, hypnozoites did not show evidence of DNA replication
as determined by microscopic analysis of their histone content.
Critically, hypnozoites persisted for at least 21 days post-sporo-
zoite infection, and future experiments will determine if even
longer persistence can be observed in this model. Our initial
observation also suggests that hypnozoite activation occurs,
as we detected a new generation of replicating schizonts at
day 21 post-sporozoite infection, but this will require more
detailed study. It might be feasible to combine the persistence
of hypnozoites in the model with the transitioning of exo-erythro-
cytic merozoites to blood stage infection, which would truly
model relapsing infection. Furthermore, it should be feasible
to test in vivo stimuli that can trigger hypnozoite activation.
Recently, a methodology for longer-term in vitro cultivation of
P. cynomolgi liver stages inMacaca fascicularis primary hepato-
cytes has been described (Dembe´le´ et al., 2014). This enabled
the observation that P. cynomolgi hypnozoites could persist,
activate, and enter liver stage schizogony. Additional pharmaco-
logical manipulation of the system with inhibitors of histone
modification enzymes accelerated the rate of hypnozoite activa-
tion. Thus, it will be of interest to determine if manipulation of
histone modifications leads to activation of P. vivax hypnozoites
in the FRG KO huHep mouse model.
While the duration of complete liver stage development for
other Plasmodium species has been experimentally determined
(for example, 6–7 days for P. falciparum [Vaughan et al., 2012]
and 7–11 days forP. cynomolgi [Krotoski et al., 1982a; Voorberg-
van der Wel et al., 2013]), our work directly determined the time
to complete P. vivax liver stage maturation and release of exo-
erythrocytic merozoites using the FRG KO huHep mouse model.
Previously, this had been extrapolated from the appearance of
blood stage parasites after experimental P. vivax sporozoite
infection of humans and nonhuman primates (Anstey et al.,
2012). In the latter, peripheral blood stage parasitemia was de-
tected as early as day 9 (for the Chesson strain) postinoculation
with very large numbers of sporozoites, suggesting that the
release of exo-erythrocytic merozoites occurred at this time
(Krotoski et al., 1982b). In agreement with this, we observed
mature liver stage schizonts containing exo-erythrocytic mero-
zoites as well as the release of merozoites at day 9 post-sporo-
zoite infection. We also observed mature schizonts on day 10
post-sporozoite infection, but their numbers had declined
when compared to day 9 infections, indicating that the peak of
liver stage schizont maturation occurs around day 9. To add
credence to our observations in the liver, we showed that
P. vivax exo-erythrocytic merozoites released from the liver onc.
days 9 and 10 after sporozoite inoculation infected reticulocytes.
Thus, the model can be used for studying the liver stage-to-
blood stage transition of P. vivax.
Successful prevention (causal prophylaxis) and treatment
(radical cure) of P. vivax hypnozoite infection require two compo-
nents: (1) prevention/elimination of the blood stage infection that
causes pathology and (2) prevention of future occurrences of
relapses by prevention/elimination of hypnozoites in the liver.
Currently, the only approved drug for causal prophylaxis
and radical cure of relapsing P. vivax infections is primaquine.
Primaquine, however, has a short half-life, requires a 2 week
dosage regimen, and has incompatibility with glucose-6-phos-
phate-dehydrogenase deficiency, which requires prescreening
of drug recipients (Kevin Baird, 2013). Therefore, there is an
ongoing search for drugs that could replace primaquine. We
showed that primaquine causal prophylaxis and treatment of
established hypnozoites prevents/eliminates P. vivax liver stage
infection in the FRG KO huHep model. We also showed that
atovaquone has little effect on hypnozoites. Thus, this mouse
model will help in accelerating the discovery of next-generation
drugs that target hypnozoites.
Taken together, our data demonstrate that the FRG KO huHep
mouse model constitutes an unprecedented, robust small ani-
mal model to support P. vivax sporozoite infection, liver stage
development, complete maturation of schizonts, and infectious
exo-erythrocytic merozoite release, as well as hypnozoite forma-
tion and persistence. The advance is of critical importance,
because questions regarding the biological basis of relapses
and their relationship to hypnozoite frequencies and activation
can now easily be addressed in vivo. This will reveal insights
into the unique biology of P. vivax and might accelerate the
development of interventions for causal prophylaxis and radical
cure of P. vivax infection.
EXPERIMENTAL PROCEDURES
Plasmodium vivax Sporozoite Production
Anopheles dirusmosquitoes (from theMahidol University colonymaintained at
the Faculty of Tropical Medicine laboratories) were infected with blood
collected from patients who were confirmed positive for only P. vivax malaria
via microscopy at local health centers in close proximity to the Kanchanaburi
Campus, Mahidol University. In brief, 150 ml of red blood cell pellet from blood
samples was suspended in pooled normal AB serum to a packed cell volume
of 50%. Then, the suspension was fed for 30 min to 100 female mosquitoes
(5–7 days old) via an artificial membrane attached to a water-jacketed glass
feeder maintained at 37C. Next, unfed mosquitoes were removed, and fed
mosquitoes were maintained on a 10% sucrose solution and incubated at
26C and 80% humidity for at least 14 days. Salivary gland dissections were
performed at days 14–19. Production of P. falciparum sporozoites and the
infection of FRG KO huHep mice with P. falciparum were performed as
previously described (Vaughan et al., 2012).
FRG KO huHep Mice
Female FRG KO mice engrafted with human hepatocytes (FRG KO huHep)
were purchased from Yecuris Corporation (Oregon, USA). The FRG KOmouse
is a triple gene knockout (Azuma et al., 2007; Bissig et al., 2007). R stands for
recombination-activating gene 2 (Rag2), and G stands for interleukin-2 recep-
tor subunit gamma (Il2rg). The Rag2/ and Il2rg/ phenotype is a severely
immunocompromised mouse lacking B, T, and NK cells that does not reject
xenotransplanted huHep. The F stands for fumarylacetoacetate hydrolase
(FAH). Due to the lack of FAH, the hepatocytes of FAH/ mice suffer buildup
of intracellular fumarylacetoacetate, resulting in their death. The phenotype is
ablated by the addition of 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexa-Cellnedione (NTBC) to the mouse diet, via the drinking water or food (Grompe
et al., 1995). FRG KO huHep mice are cycled with NTBC, which allows for
the repopulation of the mouse liver with huHeps. Repopulation levels can
reach in excess of 90%. Mice were maintained periodically on NTBC
throughout the experimental period according to the supplier’s methodology.
Enriched Human Reticulocyte Preparations
Adult human whole blood was obtained from the Thai Red Cross and depleted
from white blood cells by passage through Pall RN1 filters. The remaining re-
ticulocytes and red blood cells were washedwith RPMI1640 and concentrated
by centrifugation (1,000 g for 10 min). The blood was then overlaid on a Nycon-
denz preparation (19%) in KCl buffer and centrifuged (3,000 g for 30 min) to
separate reticulocytes from the mature red blood cells. The enriched reticulo-
cyte preparation was collected from the Nycondenz interface, washed, and
concentrated again in RPMI1640. The enrichment of reticulocytes was esti-
mated by methylene blue staining. For intravenous (IV) mouse injections,
300–400 ml of a 20%–40% enriched reticulocyte preparation was used.
In Vivo Sporozoite Infection and Liver Isolation
Mice were injected IV into the tail with 3.53 105 to 13 106 sporozoites isolated
from the salivary glands of infected mosquitoes in 100 ml of RPMI media. Mice
were euthanized at 2 (four mice), 3 (two mice), 5 (two mice), 7 (three mice), 8
(>10 mice), 9 (three mice), 10 (four mice), 14 (two mice), and 21 (three mice)
days after sporozoite infection. Livers were perfused with PBS through the
hepatic portal vein, removed, and separated into lobes. The lobes were fixed
in 4% electron microscopy grade formaldehyde in PBS, which was replaced
after 24 hr with TBS + 0.05% sodium azide. The liver lobes were then stored
at 4C in TBS containing 0.05% sodium azide. The fixed lobes were subse-
quently sliced into 25–50 mm sections for IFA. The sporozoites used for IFA
were fixed in 4% formaldehyde in PBS for 30 min. After processing for IFA,
the sporozoites were immobilized on glass slides for microscopy.
Immunofluorescence Assay
IFAs were carried out as previously described (Vaughan et al., 2009). Human
hepatocytes were detected with a rabbit anti-FAH antibody (a kind gift from
Yecuris Corporation). P. vivax liver stages were detected with a CS protein
mouse mAb (obtained from MR4, ATCC, VA), as well as rabbit polyclonal
antibodies to BiP (Noe et al., 2000), ERD2 (MR4, ATCC, VA), and MSP-1.
The polyclonal and monoclonal antibodies created for this study were devel-
oped by GenScript. In brief, codon-optimized plasmids encoding the whole or
a fragment of the protein of interest (if not full length, the amino acids used are
denoted with superscript numbers next to the name of the protein) were pro-
duced and used for immunization of animals according to the company pro-
tocols. Using this technology, antibodies to UIS479-166 (PVX_001715), HSP60
(PVX_095000), falstatin (PVX_099035), MIF (PVX_124095), AMA-144-487
(PVX_092275), and EXP-1100-148 (PVX_091700) were created. ProMab devel-
oped the mouse monoclonal antibodies to BiP (Roobsoong et al., 2014) and
ACP (PY04779, whole protein) according to the company’s protocols. For
P. vivax histone detection, anti-acetylated histone H3 rabbit antibody (Milli-
pore) was used. Fluorescence and differential interference contrast (DIC)
images were acquired using an Olympus 1 3 70 Delta Vision microscope
equipped with deconvolution software. All of the plasmids used to produce
the proteins for immunizations as well as all the antibodies described above
will be deposited in MR4 as a resource for the malaria research community.
Drug Treatment Studies
For primaquine treatment, 30 mg/kg of primaquine phosphate (Sigma) in PBS
was injected intraperitoneally (i.p.) into mice. For primaquine treatments, mice
were injected i.p. with primaquine at days 1 through 3 post-sporozoite inoc-
ulation or at days 3–7 post-sporozoite injection. For Atovaquone (Sigma)
treatment, 10 mg/kg of drug was administered orally (in 100 ml of PEG450 as
a carrier) at days1 through 1 post-sporozoite inoculation. For all drug exper-
iments, the P. vivax VK210 genotype was used. All mice were sacrificed at day
8 for analysis. NTBC was not used.
qRT-PCR
Total RNA from liver lobe samples was extracted using Trizol (Invitrogen)
and DNase treated using Turbo-DNase (Ambion). First-strand cDNA wasHost & Microbe 17, 526–535, April 8, 2015 ª2015 Elsevier Inc. 533
synthesized from RNA using the Superscript III Platinum RT Kit (Invitrogen).
The resulting cDNA was used for the amplification of human ApoAI and
P. vivax 18S rRNA cDNA (human ApoAI primers (50-AGCGTGACCTCCACC
TTCAG-30 and 50-CCTTCACCTCCTCCAGATCCTT-30; Pv18S primers, 50-GA
AGAAAATATTGGGATACGTAACAG-30 and 50-ATCGGTAGGAGCGACGGG
CG-30). The qPCR was carried out with SYBR green (Invitrogen) using the
Applied Biosystems 7300 Real-Time PCR System and associated software.
Relative copy numbers for the transcripts under study were calculated using
the DCt method. Each qPCR used identical quantities of first-strand cDNA
generated from three small sections of liver. Mice used in the experiments
were littermates, received the same donor hepatocytes, and were injected
with P. vivax sporozoites (0.8 3 106) on the same date.
Study Approval
The human blood collection protocol was approved by the Ethical Committee
of the Faculty of Tropical Medicine, Mahidol University. The study was per-
formed in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health,
USA. To this end, the Seattle Biomedical Research Institute has an Assurance
from the Public Health Service (PHS) through the Office of Laboratory Animal
Welfare (OLAW) for work approved by its Institutional Animal Care and Use
Committee (IACUC). The PHS Assurance number is A3640-01. All of the
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Seattle Biomedical Research Institute IACUC.
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